glp 1 agonists contraindications Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus Mapping the effectiveness and risks

TRIUMPH-3 (NCT05882045) will investigate change in bodyweight in people with overweight/obesity and cardiovascular disease, and TRIUMPH-4 (NCT05931367) will assess change in WOMAC score and bodyweight in individuals with overweight/obesity and knee OA

Novel approaches to diagnosis and therapy represent a growing area of interest in the management of DGp [3,4,5]

Rarely, the medications may cause thyroid cancer among high-risk patients

Sodium-glucose cotransporter-2 inhibitors, dulaglutide, and risk for dementia: a population-based cohort study

The Impending Decline of Compounded GLP-1s Compounded semaglutide and tirzepatide have been popular among patients looking to sidestep high retail prices